Login to Your Account

Merrimack smacked after HERMIONE halt of MM-302 in metastatic breast cancer

By Marie Powers
News Editor

Wednesday, December 21, 2016

Merrimack Pharmaceuticals Inc., which began 2016 with promise following its first U.S. approval, for Onivyde, has instead seen its business meander and its stock price slump this year.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription